Metastases Directed Therapy for Oligometastatic Breast Cancer

Recruiting N/A Interventional Study
Breast Cancer Metastatic Cancer Metastatic Breast Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 70
Sex
Female
Study type
Interventional
Purpose
Treatment
Participants needed
150 (estimated)
Sponsor
National Cancer Institute, Egypt · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This is a phase III randomized study evaluating the benefit from adding metastases directed therapy and locoregional treatment of the primary in breast cancer patients diagnosed with de novo oligometastatic disease patients will be randomized to receive the standard of care (SOC) treatment vs. systemic treatment + Stereotactic Ablative Radiation Therapy. Responders will be randomized to either und…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Female patients aged 18 to 70 years. * Pathological evidence of breast cancer, any grade, any T stage. * Radiological (at least) evidence of metastatic activity with maximum number of 5 extracranial lesions. * Performance status ≤ 2 * No pre-existing conditions that may prohib…
Contacts

Rimoun R Boutrus, M.D.

+201061056900

rimoun.boutrus@nci.cu.edu.eg

CONTACT

Joseph S Nayrouz, M.D.

+201272148324

j_nayrouz@yahoo.com

CONTACT